Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting

First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.(1)

Detalles Bibliográficos
Autores principales: Chien, A. Jo, Kyalwazi, Beverly, Esserman, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245052/
https://www.ncbi.nlm.nih.gov/pubmed/35732146
http://dx.doi.org/10.1016/j.xcrm.2022.100664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245052/
https://www.ncbi.nlm.nih.gov/pubmed/35732146
http://dx.doi.org/10.1016/j.xcrm.2022.100664

Ejemplares similares